🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million new cases per year. Particularly high rates are seen in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, escalating drug resistance and the extremely scarce treatment choices currently available.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm its industry partner to develop it.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

Based on findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which involves two antibiotics. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Doctors directly involved have voiced hope. Having a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is considered vital to reduce the burden of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.